Cargando…

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging

SIMPLE SUMMARY: The aim of this study was to correlate primary staging prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) parameters with either prostate final histopathology (pT) or PSMA-immunochemistry (IHC) features in a cohort of high-risk prostat...

Descripción completa

Detalles Bibliográficos
Autores principales: Vetrone, Luigia, Mei, Riccardo, Bianchi, Lorenzo, Giunchi, Francesca, Farolfi, Andrea, Castellucci, Paolo, Droghetti, Matteo, Presutti, Massimiliano, Degiovanni, Alessio, Schiavina, Riccardo, Brunocilla, Eugenio, D’Errico, Antonietta, Fanti, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046634/
https://www.ncbi.nlm.nih.gov/pubmed/36980602
http://dx.doi.org/10.3390/cancers15061716
_version_ 1785013722794688512
author Vetrone, Luigia
Mei, Riccardo
Bianchi, Lorenzo
Giunchi, Francesca
Farolfi, Andrea
Castellucci, Paolo
Droghetti, Matteo
Presutti, Massimiliano
Degiovanni, Alessio
Schiavina, Riccardo
Brunocilla, Eugenio
D’Errico, Antonietta
Fanti, Stefano
author_facet Vetrone, Luigia
Mei, Riccardo
Bianchi, Lorenzo
Giunchi, Francesca
Farolfi, Andrea
Castellucci, Paolo
Droghetti, Matteo
Presutti, Massimiliano
Degiovanni, Alessio
Schiavina, Riccardo
Brunocilla, Eugenio
D’Errico, Antonietta
Fanti, Stefano
author_sort Vetrone, Luigia
collection PubMed
description SIMPLE SUMMARY: The aim of this study was to correlate primary staging prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) parameters with either prostate final histopathology (pT) or PSMA-immunochemistry (IHC) features in a cohort of high-risk prostate cancer (PCa) patients. Our study demonstrated a correlation between higher SUVmax and IHC-PSMA expression. Moreover, we found correlations between higher total lesion PSMA (PSMA-TL) values and the risk of lymphovascular invasion (LVI), and between PSMA tumor volume (PSMA-TV) and the presence of a cribriform pattern. Our results, if validated by further studies, may help to better identify unfavorable features showed by PSMA-PET/CT in primary staging, thus improving patients’ management. ABSTRACT: PSMA-PET/CT is a suitable replacement for conventional imaging in the primary staging of PCa. The aim of this retrospective study was to assess the correlation between parameters discovered by PSMA PET/CT in primary staging and either prostate histopathology (pT) findings or PSMA-IHC expression in a cohort of biopsy-proven high-risk PCa candidates for surgery. Clinical information (age, iPSA-value, and grading group) and PSMA-PET/CT parameters (SUVmax, PSMA tumor volume [PSMA-TV], and total lesion [PSMA-TL]) were compared with pT (including histologic pattern, Gleason grade, and lymphovascular invasion [LVI]) and PSMA-IHC features, including visual quantification (VS) with a four-tiered score (0 = negative, 1+ = weak, 2+ = moderate, 3+ = strong), growth pattern (infiltrative vs expansive), and visual pattern (cytoplasmic vs membranous). In total, 44 patients were enrolled, with a median age of 67 (IQR 57-77); the median iPSA was 9.4 ng/dL (IQR 12.5-6.0). One patient (3%) was grading group (GG) 3, 27/44 (61%) were GG4, and 16/44 (36%) were GG5. PSMA-PET/CT detection rate for the presence of primary prostate cancer was 100%. Fused/poorly formed Gleason grade 4 features were predominant (22/44–50%); a cribriform pattern was present in 18/44 (41%) and acinar in 4/44 (9%). We found that lower PSMA-TVs were mostly related to acinar, while higher PSMA-TVs correlated with a higher probability to have a cribriform pattern (p-value 0.04). LVI was present in 21/44(48%) patients. We found that higher PSMA-TV and PSMA-TL are predictive of LVI p-value 0.002 and p-value 0.01, respectively. There was no correlation between PET-parameters and perineural invasion (PNI), probably because this was present in almost all the patients. Moreover, patients with high PSMA-TL values displayed the highest PSMA-IHC expression (VS3+) with a membranous pattern. In conclusion, PSMA-TV and PSMA-TL are predictors of a cribriform pattern and LVI. These conditions are mostly related to higher aggressiveness and worse outcomes.
format Online
Article
Text
id pubmed-10046634
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100466342023-03-29 Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging Vetrone, Luigia Mei, Riccardo Bianchi, Lorenzo Giunchi, Francesca Farolfi, Andrea Castellucci, Paolo Droghetti, Matteo Presutti, Massimiliano Degiovanni, Alessio Schiavina, Riccardo Brunocilla, Eugenio D’Errico, Antonietta Fanti, Stefano Cancers (Basel) Article SIMPLE SUMMARY: The aim of this study was to correlate primary staging prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) parameters with either prostate final histopathology (pT) or PSMA-immunochemistry (IHC) features in a cohort of high-risk prostate cancer (PCa) patients. Our study demonstrated a correlation between higher SUVmax and IHC-PSMA expression. Moreover, we found correlations between higher total lesion PSMA (PSMA-TL) values and the risk of lymphovascular invasion (LVI), and between PSMA tumor volume (PSMA-TV) and the presence of a cribriform pattern. Our results, if validated by further studies, may help to better identify unfavorable features showed by PSMA-PET/CT in primary staging, thus improving patients’ management. ABSTRACT: PSMA-PET/CT is a suitable replacement for conventional imaging in the primary staging of PCa. The aim of this retrospective study was to assess the correlation between parameters discovered by PSMA PET/CT in primary staging and either prostate histopathology (pT) findings or PSMA-IHC expression in a cohort of biopsy-proven high-risk PCa candidates for surgery. Clinical information (age, iPSA-value, and grading group) and PSMA-PET/CT parameters (SUVmax, PSMA tumor volume [PSMA-TV], and total lesion [PSMA-TL]) were compared with pT (including histologic pattern, Gleason grade, and lymphovascular invasion [LVI]) and PSMA-IHC features, including visual quantification (VS) with a four-tiered score (0 = negative, 1+ = weak, 2+ = moderate, 3+ = strong), growth pattern (infiltrative vs expansive), and visual pattern (cytoplasmic vs membranous). In total, 44 patients were enrolled, with a median age of 67 (IQR 57-77); the median iPSA was 9.4 ng/dL (IQR 12.5-6.0). One patient (3%) was grading group (GG) 3, 27/44 (61%) were GG4, and 16/44 (36%) were GG5. PSMA-PET/CT detection rate for the presence of primary prostate cancer was 100%. Fused/poorly formed Gleason grade 4 features were predominant (22/44–50%); a cribriform pattern was present in 18/44 (41%) and acinar in 4/44 (9%). We found that lower PSMA-TVs were mostly related to acinar, while higher PSMA-TVs correlated with a higher probability to have a cribriform pattern (p-value 0.04). LVI was present in 21/44(48%) patients. We found that higher PSMA-TV and PSMA-TL are predictive of LVI p-value 0.002 and p-value 0.01, respectively. There was no correlation between PET-parameters and perineural invasion (PNI), probably because this was present in almost all the patients. Moreover, patients with high PSMA-TL values displayed the highest PSMA-IHC expression (VS3+) with a membranous pattern. In conclusion, PSMA-TV and PSMA-TL are predictors of a cribriform pattern and LVI. These conditions are mostly related to higher aggressiveness and worse outcomes. MDPI 2023-03-10 /pmc/articles/PMC10046634/ /pubmed/36980602 http://dx.doi.org/10.3390/cancers15061716 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vetrone, Luigia
Mei, Riccardo
Bianchi, Lorenzo
Giunchi, Francesca
Farolfi, Andrea
Castellucci, Paolo
Droghetti, Matteo
Presutti, Massimiliano
Degiovanni, Alessio
Schiavina, Riccardo
Brunocilla, Eugenio
D’Errico, Antonietta
Fanti, Stefano
Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging
title Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging
title_full Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging
title_fullStr Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging
title_full_unstemmed Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging
title_short Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging
title_sort histology and psma expression on immunohistochemistry in high-risk prostate cancer patients: comparison with (68)ga-psma pet/ct features in primary staging
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046634/
https://www.ncbi.nlm.nih.gov/pubmed/36980602
http://dx.doi.org/10.3390/cancers15061716
work_keys_str_mv AT vetroneluigia histologyandpsmaexpressiononimmunohistochemistryinhighriskprostatecancerpatientscomparisonwith68gapsmapetctfeaturesinprimarystaging
AT meiriccardo histologyandpsmaexpressiononimmunohistochemistryinhighriskprostatecancerpatientscomparisonwith68gapsmapetctfeaturesinprimarystaging
AT bianchilorenzo histologyandpsmaexpressiononimmunohistochemistryinhighriskprostatecancerpatientscomparisonwith68gapsmapetctfeaturesinprimarystaging
AT giunchifrancesca histologyandpsmaexpressiononimmunohistochemistryinhighriskprostatecancerpatientscomparisonwith68gapsmapetctfeaturesinprimarystaging
AT farolfiandrea histologyandpsmaexpressiononimmunohistochemistryinhighriskprostatecancerpatientscomparisonwith68gapsmapetctfeaturesinprimarystaging
AT castelluccipaolo histologyandpsmaexpressiononimmunohistochemistryinhighriskprostatecancerpatientscomparisonwith68gapsmapetctfeaturesinprimarystaging
AT droghettimatteo histologyandpsmaexpressiononimmunohistochemistryinhighriskprostatecancerpatientscomparisonwith68gapsmapetctfeaturesinprimarystaging
AT presuttimassimiliano histologyandpsmaexpressiononimmunohistochemistryinhighriskprostatecancerpatientscomparisonwith68gapsmapetctfeaturesinprimarystaging
AT degiovannialessio histologyandpsmaexpressiononimmunohistochemistryinhighriskprostatecancerpatientscomparisonwith68gapsmapetctfeaturesinprimarystaging
AT schiavinariccardo histologyandpsmaexpressiononimmunohistochemistryinhighriskprostatecancerpatientscomparisonwith68gapsmapetctfeaturesinprimarystaging
AT brunocillaeugenio histologyandpsmaexpressiononimmunohistochemistryinhighriskprostatecancerpatientscomparisonwith68gapsmapetctfeaturesinprimarystaging
AT derricoantonietta histologyandpsmaexpressiononimmunohistochemistryinhighriskprostatecancerpatientscomparisonwith68gapsmapetctfeaturesinprimarystaging
AT fantistefano histologyandpsmaexpressiononimmunohistochemistryinhighriskprostatecancerpatientscomparisonwith68gapsmapetctfeaturesinprimarystaging